Novacyt S.A. (AIM:NCYT)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 25.41M |
| Revenue (ttm) | 19.45M |
| Net Income (ttm) | -30.40M |
| Shares Out | n/a |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,960 |
| Average Volume | 44,880 |
| Open | 35.20 |
| Previous Close | 36.80 |
| Day's Range | 34.10 - 36.40 |
| 52-Week Range | 32.80 - 54.00 |
| Beta | n/a |
| RSI | 55.08 |
| Earnings Date | Apr 30, 2026 |
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the... [Read more]
Financial Performance
In 2024, Novacyt's revenue was 19.63 million, an increase of 84.82% compared to the previous year's 10.62 million. Losses were -41.76 million, 47.6% more than in 2023.
Financial StatementsNews
Novacyt makes Australian acquisition to accelerate global growth
Novacyt's acquisition of Southern Cross Diagnostics via its wholly owned subsidiary will give it a bigger overseas footprint.
Novacyt S.A. (NVYTF) Discusses Interim Results, Growth Strategy, and New Product Introduction Prepared Remarks Transcript
Novacyt S.A. (OTCPK:NVYTF) Discusses Interim Results, Growth Strategy, and New Product Introduction October 22, 2025 2:00 AM EDT Company Participants Lyn Rees - CEO & Executive Director Steve Gibson -...
Novacyt S.A. (NVYTF) Q4 2024 Earnings Call Transcript
Novacyt SA (NVYTF) Q2 2024 Earnings Call Transcript Highlights: Key Financial Metrics and ...
Novacyt SA (NVYTF) Q2 2024 Earnings Call Transcript Highlights: Key Financial Metrics and Strategic Insights
Half Year 2024 Novacyt SA Earnings Call Transcript
Half Year 2024 Novacyt SA Earnings Call Transcript
Novacyt S.A. (NVYTF) Q2 2024 Earnings Call Transcript
Novacyt S.A. (NVYTF) Q4 2023 Earnings Call Transcript
Novacyt S.A. (OTCPK:NVYTF) Q4 2023 Earnings Conference Call May 30, 2024 6:00 AM ET Company Participants Lyn Rees - CEO Steve Gibson - CFO Conference Call Participants Operator [abrupt start] and welc...
Novacyt S.A. (NVYTF) Q2 2023 Earnings Call Transcript
Novacyt S.A. (OTC:NVYTF) Q2 2023 Earnings Conference Call September 28, 2023 7:30 AM ET Company Participants James McCarthy - Acting CEO Steve Gibson - Group Finance Director Lyn Rees - Executive Dire...
Novacyt S.A. (NVYTF) Q4 2022 Earnings Call Transcript
Novacyt S.A. (OTCPK:NVYTF) Q4 2022 Results Conference Call April 27, 2023 7:00 AM ET Company Participants James McCarthy - Acting Chief Executive Officer Steve Gibson - Group Finance Director Operator...
Novacyt S.A. (NVYTF) Q2 2022 Earnings Call Transcript
Novacyt S.A. (OTCPK:NVYTF) Q2 2022 Earnings Conference Call September 29, 2022 7:00 AM ET Company Participants David Allmond - Chief Executive Officer James McCarthy - Chief Financial Officer Conferen...
Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Half Year 2022 Results
PARIS & CAMBERLEY, England--(BUSINESS WIRE)--Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited results for the ...